Biomarker analyses conducted in a subset of nonhospitalised patients with COVID-19 show that treatment with remdesivir improves several markers associated with the immune and blood clotting systems compared with placebo.

These findings were based on a secondary analysis of a phase 3 clinical trial by the pharmaceutical company Gilead. The...